Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GH
stocks logo

GH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
267.60M
+32.6%
-0.475
-23.42%
271.00M
+33.19%
-0.440
-10.15%
295.66M
+27.39%
-0.390
-11.43%
Estimates Revision
The market is revising No Change the revenue expectations for Guardant Health, Inc. (GH) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by 80.48%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.22%
In Past 3 Month
Stock Price
Go Up
up Image
+80.48%
In Past 3 Month
Wall Street analysts forecast GH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 88.00 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast GH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 88.00 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Buy
0 Hold
0 Sell
Strong Buy
Current: 108.520
sliders
Low
60.00
Averages
88.00
High
120.00
Current: 108.520
sliders
Low
60.00
Averages
88.00
High
120.00
Piper Sandler
NULL -> Overweight
upgrade
$90 -> $120
2025-11-10
Reason
Piper Sandler
Price Target
$90 -> $120
2025-11-10
upgrade
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on Guardant Health to $120 from $90 following quarterly results. The firm keeps an Overweight rating on the shares.
Stifel
Daniel Arias
Buy
maintain
$70 -> $100
2025-11-03
Reason
Stifel
Daniel Arias
Price Target
$70 -> $100
2025-11-03
maintain
Buy
Reason
Stifel analyst Daniel Arias raised the firm's price target on Guardant Health to $100 from $70 and keeps a Buy rating on the shares. The firm's Q3 results were "particularly strong," with a robust top-line and a boost to its FY25 guidance, the analyst tells investors. Stifel believes the ongoing business momentum can support the stock momentum.
Citi
Buy
upgrade
$65 -> $100
2025-10-30
Reason
Citi
Price Target
$65 -> $100
2025-10-30
upgrade
Buy
Reason
Citi raised the firm's price target on Guardant Health to $100 from $65 and keeps a Buy rating on the shares. The firm says the company's momentum continues following the "beat and raise" Q3 print.
UBS
Dan Leonard
Buy
maintain
$80 -> $110
2025-10-30
Reason
UBS
Dan Leonard
Price Target
$80 -> $110
2025-10-30
maintain
Buy
Reason
UBS analyst Dan Leonard raised the firm's price target on Guardant Health to $110 from $80 and keeps a Buy rating on the shares. With another beat and raise, UBS sees multiple catalysts ahead for Guardant Health, the analyst tells investors in a research note.
Barclays
Overweight
maintain
$70 -> $85
2025-10-30
Reason
Barclays
Price Target
$70 -> $85
2025-10-30
maintain
Overweight
Reason
Barclays raised the firm's price target on Guardant Health to $85 from $70 and keeps an Overweight rating on the shares following the earnings report. Guardant is "firing on all cylinders," with a broad-based beat across oncology, biopharma and screening, the analyst tells investors in a research note. The firm sees "plenty of opportunities" for the company's growth trajectory to continue into 2026.
Canaccord
Kyle Mikson
Buy
maintain
$75 -> $100
2025-10-30
Reason
Canaccord
Kyle Mikson
Price Target
$75 -> $100
2025-10-30
maintain
Buy
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Guardant Health to $100 from $75 and keeps a Buy rating on the shares. The firm said their target increase is driven by increased revenue growth and operating margin expansion in the out years of our 10-year DCF model. Canaccord noted they reported 3Q25 results that were well ahead of firm estimates and FactSet consensus. Guardant's performance was driven by broad-based growth in revenue and volume.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Guardant Health Inc (GH.O) is -66.74, compared to its 5-year average forward P/E of -20.13. For a more detailed relative valuation and DCF analysis to assess Guardant Health Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-20.13
Current PE
-66.74
Overvalued PE
-6.10
Undervalued PE
-34.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-22.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-5.93
Undervalued EV/EBITDA
-38.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.40
Current PS
0.00
Overvalued PS
23.62
Undervalued PS
1.18
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 473.26% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 473.26% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GH News & Events

Events Timeline

(ET)
2025-12-01
16:30:00
Morgan Stanley Assigns Overweight Rating to Guardant Health with $130 Price Target
select
2025-11-05 (ET)
2025-11-05
16:50:34
Guardant Health reveals results of Shield blood-based screening test
select
2025-11-05
05:30:50
Guardant Health Prices 3.33M Share Spot Secondary Offering at $90.00
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Benzinga
Senator Acquires Coca-Cola and Hershey's Shares Following Sale of Magnificent Seven Stocks in 2025

  • Senator's Recent Stock Purchases: Senator Sheldon Whitehouse disclosed the purchase of three stocks on November 21, 2025, including Hershey Co, Coca-Cola Co, and Guardant Health, each valued between $1,000 to $15,000.

  • Previous Trading Activity: This marks Whitehouse's first stock buys in 2025, with previous transactions involving sales of Magnificent Seven stocks like Apple and NVIDIA throughout 2024 and 2025.

  • Investor Interest in Congressional Trades: While Whitehouse's trading activity is less followed compared to other members of Congress, retail investors are encouraged to monitor various lawmakers' trades, especially with Nancy Pelosi retiring in 2026.

  • Market Context: The purchases are relatively small compared to Whitehouse's past transactions, and the article highlights the ongoing interest in how congressional trading can impact market performance.

[object Object]
Preview
2.0
11-23Benzinga
Top 10 Large-Cap Gainers Last Week (Nov. 17-Nov. 21): Alphabet, Exact Sciences, and Regeneron Lead the Pack—Is Your Portfolio Included?

  • Top Stock Performers: Exact Sciences Corporation surged 48.97% after Abbott Laboratories announced its acquisition for $105 per share, while other notable gainers included Jazz Pharmaceuticals (3.75%), Natera (12.90%), and Amer Sports (12.86%) due to positive financial results and analyst upgrades.

  • Analyst Ratings and Forecasts: Natera received a price forecast increase from UBS, Amer Sports raised its FY25 guidance, and Lumentum Holdings was initiated with an Outperform rating and a price target of $290 by Mizuho.

  • Acquisitions and Buybacks: Solventum Corporation announced its acquisition of Acera Surgical for $725 million and a $1 billion stock buyback plan, while Guardant Health and Regeneron Pharmaceuticals also saw significant gains this week.

  • Regulatory Challenges for Alphabet: Alphabet Inc. gained 4.9% as it criticized the DOJ's proposal to break up Google Ad Manager, arguing it would create uncertainty for advertisers and publishers while vowing to seek a resolution that supports business growth.

[object Object]
Preview
2.0
11-21SeekingAlpha
LLY enters the $1 trillion club but is absent from South Africa's top 10 large-cap healthcare stocks.

  • Eli Lilly's Milestone: Eli Lilly (LLY) has officially joined the group of U.S. companies valued at over $1 trillion, becoming the tenth American stock to reach this milestone, driven by strong investor interest in its GLP-1 drug franchise.

  • Quant Ratings Position: Despite its trillion-dollar valuation, Eli Lilly does not rank among the top ten healthcare stocks according to Seeking Alpha's Quant Ratings, where it holds a score of 3.47, placing it outside the upper tier of healthcare companies.

  • Top-Rated Healthcare Stocks: The highest-rated healthcare stocks based on Seeking Alpha's Quant Grades include Guardant Health, Incyte Corporation, and Pfizer, with ratings ranging from 4.95 to 4.91.

  • Investment Opportunities: Investors looking to diversify their exposure to the healthcare sector can consider various exchange-traded funds (ETFs) that focus on this industry.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Guardant Health Inc (GH) stock price today?

The current price of GH is 108.52 USD — it has increased 2.42 % in the last trading day.

arrow icon

What is Guardant Health Inc (GH)'s business?

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

arrow icon

What is the price predicton of GH Stock?

Wall Street analysts forecast GH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 88.00 USD with a low forecast of 60.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Guardant Health Inc (GH)'s revenue for the last quarter?

Guardant Health Inc revenue for the last quarter amounts to 265.20M USD, increased 38.50 % YoY.

arrow icon

What is Guardant Health Inc (GH)'s earnings per share (EPS) for the last quarter?

Guardant Health Inc. EPS for the last quarter amounts to -0.74 USD, decreased -15.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Guardant Health Inc (GH)'s fundamentals?

The market is revising No Change the revenue expectations for Guardant Health, Inc. (GH) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by 80.48%.
arrow icon

How many employees does Guardant Health Inc (GH). have?

Guardant Health Inc (GH) has 1999 emplpoyees as of December 05 2025.

arrow icon

What is Guardant Health Inc (GH) market cap?

Today GH has the market capitalization of 14.04B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free